Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.

OBJECTIVE To describe tumor control following intra-arterial chemotherapy (IAC) for retinoblastoma. METHODS A retrospective interventional series in which 17 patients were treated with ophthalmic artery injection of melphalan, 5 mg, was undertaken to determine retinoblastoma control. RESULTS Of 190 children with retinoblastoma, 17 (9%) were treated with IAC. Catheterization was successful in 37 of 38 attempts. The treatment was primary in 13 cases (1 failed catheterization) and secondary in 4. The median retinoblastoma base was 20 mm and the median retinoblastoma thickness was 9.0 mm. Iris neovascularization was present in 5 cases. Following IAC, complete response of the main tumor was found in 14 cases (88%) and partial response was found in 2 (12%). Eyes with complete response and followed up for a minimum of 1 year (n = 10) showed no solid tumor recurrence. Of 11 eyes with subretinal seeds, 9 (82%) had complete response, 1 (9%) had partial response, and 1 (9%) had recurrence. Of 9 eyes with vitreous seeds, 6 (67%) had complete response, 2 (22%) had partial response, and 1 (11%) had recurrence. Globe salvage was achieved in 8 of 12 eyes (67%) treated with primary IAC, including 2 of 2 group C eyes, 4 of 4 group D eyes, and 2 of 6 group E eyes according to the International Classification of Retinoblastoma. Globe salvage was achieved in 2 of 4 eyes (50%) treated secondarily after failure of other methods. CONCLUSIONS Of 12 eyes managed with IAC as primary treatment, globe salvage was achieved in 67%. Eyes classified as group C or D showed 100% globe salvage, whereas group E had 33% salvage. Of 4 eyes managed with IAC as secondary treatment, globe salvage was achieved in 50%.

[1]  C. Shields,et al.  Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. , 2011, Archives of ophthalmology.

[2]  C. Shields,et al.  Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. , 2011, Archives of ophthalmology.

[3]  C. Shields,et al.  Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? , 2010, Archives of ophthalmology.

[4]  C. Shields,et al.  Intra‐arterial chemotherapy for retinoblastoma: the beginning of a long journey , 2010, Clinical & experimental ophthalmology.

[5]  S. Brodie,et al.  Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). , 2010, Ophthalmology.

[6]  C. Shields,et al.  Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy , 2010, Current opinion in ophthalmology.

[7]  D. Abramson Super selective ophthalmic artery delivery of chemotherapy for intraocular retinoblastoma: ‘chemosurgery’The first Stallard lecture , 2010, British Journal of Ophthalmology.

[8]  S. Brodie,et al.  Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. , 2010, Archives of ophthalmology.

[9]  C. Shields,et al.  Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma. , 2009, Retina.

[10]  C. Shields,et al.  Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. , 2009, Archives of ophthalmology.

[11]  C. Shields,et al.  Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. , 2009, Ophthalmology.

[12]  D. Abramson,et al.  Retinoblastoma: what is new in 2007–2008 , 2008, Current opinion in ophthalmology.

[13]  S. Brodie,et al.  A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. , 2008, Ophthalmology.

[14]  A. B. Reese,et al.  Management of retinoblastoma , 2008, Annals of the New York Academy of Sciences.

[15]  D. Abramson,et al.  Abstract No. 60: A Phase I/II Study of Intra-Arterial (Ophthalmic Artery) Chemotherapy for Intraocular Retinoblastoma , 2008 .

[16]  W. Shi,et al.  A phase II trial of carboplatin for intraocular retinoblastoma , 2007, Pediatric blood & cancer.

[17]  C. Shields,et al.  Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. , 2004, American journal of ophthalmology.

[18]  A. Kaneko,et al.  The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma , 2004, International Journal of Clinical Oncology.

[19]  A. Kaneko,et al.  Management of intraocular retinoblastoma and ocular prognosis , 2004, International Journal of Clinical Oncology.

[20]  C. Shields,et al.  Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. , 2002, Archives of ophthalmology.

[21]  F. Ferris,et al.  A new era for the treatment of retinoblastoma. , 1996, Archives of ophthalmology.

[22]  A. Kaneko,et al.  Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. , 1987, Japanese journal of cancer research : Gann.

[23]  J. Hainsworth,et al.  Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. , 1986, Annals of internal medicine.

[24]  G. Bosl,et al.  Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. , 1981, Annals of internal medicine.

[25]  M. Kiribuchi [Retrograde infusion of anti-cancer drugs to ophthalmic artery for intraocular malignant tumors]. , 1966, Nippon Ganka Gakkai zasshi.

[26]  A. B. Reese,et al.  The treatment of retinoblastoma by x-ray and triethylene melamine. , 1958, A.M.A. archives of ophthalmology.

[27]  L. Jampol Superselective Catheterization of the Ophthalmic Artery for Intraarterial Chemotherapy for Retinoblastoma , 2009 .

[28]  C. Shields,et al.  The International Classification of Retinoblastoma predicts chemoreduction success. , 2006, Ophthalmology.